O
BOLT icon

OrbiMed’s Bolt Biotherapeutics BOLT Stock Holding History

OrbiMed’s Portfolio BOLT Stock Details BOLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-77,050
Closed -$2.16M – 118
2024
Q1 		$2.16M Hold
77,050
– – 0.04% 103
2023
Q4 		$1.73M Hold
77,050
– – 0.03% 99
2023
Q3 		$1.6M Hold
77,050
– – 0.03% 116
2023
Q2 		$1.97M Hold
77,050
– – 0.04% 116
2023
Q1 		$2.14M Buy
77,050
+38,497
+100% +$1.13M 0.04% 112
2022
Q4 		$1M Hold
38,553
– – 0.02% 110
2022
Q3 		$1.14M Buy
+38,553
New +$1.6M 0.02% 126

Other funds holding BOLT

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $308M AUM 120.89% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $533M AUM 65.58% 1-Year Est. Return

OrbiMed's BOLT Position: Q2 2024 in Review

OrbiMed sold out of Bolt Biotherapeutics (BOLT) in Q2 2024, closing a stake of 77,050 shares — an estimated $2.16M sold.

OrbiMed first reported a position in BOLT in Q3 2022 and held it in 7 quarters. The position peaked at $2.16M in Q1 2024. 36 funds tracked by Wall St. Rank hold BOLT as of Q2 2024.

  • OrbiMed reported no remaining Bolt Biotherapeutics position as of Q2 2024 after selling out during the quarter.
  • OrbiMed sold 77,050 Bolt Biotherapeutics shares in Q2 2024, an estimated $2.16M.
  • OrbiMed first reported a position in Bolt Biotherapeutics in Q3 2022 and held it in 7 quarters.
  • OrbiMed's Bolt Biotherapeutics position peaked at $2.16M in Q1 2024.
  • 36 funds tracked by Wall St. Rank held Bolt Biotherapeutics as of Q2 2024.

Based on OrbiMed's 13F filing for Q2 2024, filed 14 Aug 2024.